Soluble urokinase plasminogen activator receptor as a marker for use of antidepressants.
<h4>Objectives</h4>Inflammation is involved in the pathogenesis of depression. A few cross-sectional population-based studies have found that depression is associated with increased levels of inflammatory markers. Soluble urokinase plasminogen activation receptor (suPAR) is known to be a...
Guardado en:
Autores principales: | Eva Haastrup, Katrine Grau, Jesper Eugen-Olsen, Christian Thorball, Lars Vedel Kessing, Henrik Ullum |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/18601855b7964800aa51a051d0b182a9 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation
por: Line Jee Hartmann Rasmussen, et al.
Publicado: (2021) -
Eleven genomic loci affect plasma levels of chronic inflammation marker soluble urokinase-type plasminogen activator receptor
por: Joseph Dowsett, et al.
Publicado: (2021) -
Extracellular matrix biomarker, fibulin-1, is closely related to NT-proBNP and soluble urokinase plasminogen activator receptor in patients with aortic valve stenosis (the SEAS study).
por: Ruan Kruger, et al.
Publicado: (2014) -
Soluble Urokinase Plasminogen Activator Receptor (suPAR) Independently Predicts Severity and Length of Hospitalisation in Patients With COVID-19
por: Helena Enocsson, et al.
Publicado: (2021) -
Soluble urokinase-type plasminogen activator receptor (suPAR) is a risk indicator for eGFR loss in kidney transplant recipients
por: Ulrich Jehn, et al.
Publicado: (2021)